ceritinib; pelitinib (Zykadia)

Indications

• metastatic non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase positive, previously treated with crizotinib

Adverse effects

• diarrhea, nausea, vomiting, abdominal pain
• increased lserum transaminases
• increased serum amylase & serum lipase
• increased serum glucose

• drug adverse effects of tyrosine kinase inhibitor(s)

Mechanism of action

• inhibits anaplastic lymphoma kinase (ALK)

More general terms

• small inhibitory antineoplastic agent (ib drug)
• antineoplastic tyrosine kinase inhibitor

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6445562
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=71751477